Showing results (131-140 of 483) with videos related to

Sort By:
Pageof 49
Cancer|March 3, 2007
The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myelomaMarius Horger, Lothar Kanz, Barbara Denecke, et al.
Leukemia & Lymphoma|June 28, 2021
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myelomaDavid Siegel, Katja Weisel, Anita Zahlten-Kumeli, et al.
Annals of Hematology|July 1, 2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatmentManola Zago, Katharina Oehrlein, Corinna Rendl, et al.
Annals of Hematology|November 16, 2022
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experienceSusanne Ghandili, Dzenefa Alihodzic, Christian Wiessner, et al.
AJR. American Journal of Roentgenology|May 25, 2012
Perfusion and flow extraction product as potential discriminators in untreated follicular and diffuse large B cell lymphomas using volume perfusion CT with attempt at histopathologic explanationDaniel Spira, Patrick Adam, Catharina Linder, et al.
Academic Radiology|October 8, 2010
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenibDaniel Spira, Michael Fenchel, Ulrich M Lauer, et al.
AJR. American Journal of Roentgenology|December 24, 2009
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessmentOlga Maksimovic, Christina Schraml, Joerg T Hartmann, et al.
AJR. American Journal of Roentgenology|August 24, 2012
Systemic IgG4-related sclerosing disease: spectrum of imaging findings and differential diagnosisMarius Horger, Hans-Georg Lamprecht, Roland Bares, et al.
Haematologica|December 30, 2006
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphomaJörg T Hartmann, Ines Meisinger, Stefan M Kröber, et al.
Transfusion|September 25, 2014
Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusionChristof Weinstock, Robert Möhle, Christiane Dorn, et al.
Pageof 49